ATTENTION NASDAQ: QURE INVESTORS: Contact Berger Montague About an uniQure N.V. Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the effectiveness of its gene therapy candidate AMT-130 and the likelihood of FDA approval [1][3]. Company Overview - uniQure, based in Amsterdam, specializes in developing and commercializing gene therapies for severe diseases, particularly focusing on Huntington's disease and other neurological disorders [2]. Legal Proceedings - The lawsuit pertains to investors who acquired uniQure securities between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiff appointments [2]. - The complaint claims that uniQure misrepresented the effectiveness of AMT-130 and the status of FDA agreement on study endpoints, which led to a significant stock price increase of nearly 250% from $13.66 to $47.50 per share shortly after the misleading statements [3]. Stock Performance - Following the revelation on November 3, 2025, that the FDA agreement on study design was not finalized, uniQure's stock plummeted over 49%, dropping from $67.69 to $34.29 per share [4].